Pharmosa Biopharm Inc. (TPEX:6875)

Market Cap	4.76B -31.1%
Revenue (ttm)	67.27M -59.9%
Net Income	-383.85M
EPS	-2.97
Shares Out	129.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	163,099
Average Volume	73,872
Open	37.40
Previous Close	37.40
Day's Range	36.85 - 37.50
52-Week Range	36.85 - 65.00
Beta	0.28
RSI	33.48
Earnings Date	May 11, 2026

About Pharmosa Biopharm

Pharmosa Biopharm Inc., a biotechnology company, focuses on developing drugs in Taiwan. It develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease. The company was formerly known as Pharmosa Limited and changed its name to Pharmosa Biopharm Inc. in October 2016. Pharmosa Biopharm Inc. was founded in 2000 and is headquartered in Taipei, Taiwan...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 40
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6875

Financial Performance

In 2025, Pharmosa Biopharm's revenue was 67.27 million, a decrease of -59.86% compared to the previous year's 167.57 million. Losses were -383.85 million, 130.3% more than in 2024.